London close: Stocks slump on global manufacturing data
22nd Mar 2012 16:57
- PMIs disappoint from China and Eurozone - Miners down on demand concerns, Randgold plummets on Malian military coup - Broker downgrades weigh on stocks After a steep fall early on, London's blue chips traded broadly sideways for the remainder of the day as gloomy economic data weighed on senti
Read moreAstraZeneca patent invalid, UK court rules
22nd Mar 2012 12:13
Drugs giant AstraZeneca has admitted that the formulation patent protecting its Seroquel XR product was deemed invalid by the High Court in the UK. The patent was challenged by Accord Healthcare, Intas Pharmaceuticals, Hexal AG and Sandoz, Teva UK, and Teva Pharmaceutical Industries. Astra assured
Read moreLondon midday: Macro data weighs on stocks
22nd Mar 2012 11:43
- PMIs disappoint from China and Eurozone - Miners down on demand concerns, Randgold plummets on Malian military coup - Broker downgrades weigh on stocks The Footsie was firmly lower by lunchtime as a result of heavy losses in the mining sector on the back of some gloomy economic data from China.
Read moreThursday broker round-up
22nd Mar 2012 09:58
AMEC: JP Morgan Cazenove downgrades from overweight to neutral, target lifted from 1,252p to 1,344p. AstraZeneca: Liberium Capital upgrades from sell to buy, target lifted from 2,700p to 3,100p. British Land: Espirto Santo downgrades from buy to neutral. Capital Shopping Centres Group: Societe Ge
Read moreLondon open: Miners pull the Footsie lower
20th Mar 2012 08:36
- Miners fall as BHP warns of slowing steel production in China - OBR to raise UK GDP forecasts for 2012 - ARM, National Grid, United Utilities rise after upgrades The FTSE 100 slumped in the opening hour on Tuesday as the miners dragged the blue chip index into the red for a second day. According
Read moreAnother setback for Astra
20th Mar 2012 07:21
Concerns about Anglo-Swedish drugs giant AstraZeneca's pipeline are likely to increase as the company abandoned work on its anti-depressant treatment TC-5214, which it developed in conjunction with US peer Targacept. The two companies said top-line results from the remaining Phase 3 studies did no
Read moreMonday broker round-up - UPDATE
19th Mar 2012 09:37
Antofagasta: Exane BNP Paribas upgrades from neutral to outperform, target lifted from 1,200p to 1,450p; Nomura cuts target to 1,500p from 1,650p, buy rating unchanged. AstraZeneca: Goldman Sachs cuts target from 3,350p to 3,306p, neutral rating kept. Barclays: UBS raises target from 240p to 272p,
Read moreSunday tip round-up: Dogs of the FTSE, Investors´ favourites
18th Mar 2012 14:07
Since the year 2000 experience seems to show that investing in the highest yielding stocks of the UK´s benchmark index, when the economy is recovering, can be a sound strategy. Therefore, given signs that the worst is over the Midas team at the Daily Mail has decided to re-launch their 'Dogs of the
Read moreMoody's: Pharma firms' ratings could be under pressure
14th Mar 2012 14:36
Ratings agency Moody's has announced that certain European pharmaceuticals companies' ratings could be pressured by resumed share buy-backs. Four of the largest pharma groups, namely AstraZeneca, GlaxoSmithSkline (GSK), Novartis and Sanofi, could all be at risk after they re-started share buy-back
Read moreTuesday broker round-up - UPDATE
13th Mar 2012 09:59
AstraZeneca: Panmure Gordon keeps buy rating and 3,600p target. Bellway: Credit Suisse maintains outperform rating. BG Group: Nomura raises target from 1,865p to 1,950p, buy rating kept. Computacenter: Panmure Gordon ups target from 490p to 501p, buy rating unchanged. Hays: Credit Suisse ups tar
Read moreLondon open: Financials, miners lead the rise
13th Mar 2012 08:38
- Standard Life, Pru in demand after results - Antofagasta, G4S lead the fallers - BoJ maintains rates, ups asset purchases The Footsie rose strongly on Tuesday helped by some well-received full-year results from insurers and a decent performance by banking and mining stocks as risk appetite increa
Read moreAstra sues FDA over generic versions of SEROQUEL
13th Mar 2012 07:20
Drugs giant AstraZeneca has filed a lawsuit against US regulators to overturn last week's denial of petitions with regard to generic versions of its SEROQUEL and SEROQUEL XR tablets. The tablets, also know as 'quetiapine fumarate', are an antispsychotic drug used in the treatment of schizophrenia,
Read moreLondon open: Stocks fall ahead of Greek debt-swap
6th Mar 2012 08:33
- IIF warns of 1trn euro damage to Eurozone. - Fresnillo bucks sector trend to rise after results. - Defensives in demand. With just a couple days to go before the Greek debt-swap deadline, investors were in a cautious mood as the Footsie slipped lower in early trading on Tuesday. Europe is awaiti
Read moreSector movers: Miners tumble on Chinese demand worries
5th Mar 2012 16:12
China's decision to lower its forecast for growth in 2012 knocked resource companies from the off today, with mining stocks being down an average 3.42 percent in afternoon trade. Wen Jiabao, the Premier of the world's second-largest economy, revealed that the country had reduced its gross domestic
Read moreFTSE 100 movers: Going overboard on Man
1st Mar 2012 12:29
Investors were going overboard on Man Group following the announcement of a more generous dividend policy and a slow-down in the net outflow of funds at the hedge fund manager. The group said funds under management (FUM) at the end of February clocked in at around $59.5bn, up from the end of 2011
Read more